News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Cristina Solis-Pomales

Articles by Cristina Solis-Pomales

45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?

ByAmy Jeng,Cristina Solis-Pomales,Kseniya Roudakova,J. Jamie Alberty-Oller

May 26th 2024

62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population

ByKseniya Roudakova,Cristina Solis-Pomales,Amy Jeng,J. Jaime Alberty-Oller

May 9th 2024

Latest Updated Articles

45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
May 26th 2024

Trending on CancerNetwork

FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy

Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview

Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC

Toripalimab Regimen Improves EFS, MPR Rate in Stage II/III NSCLC Trial

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1